Product Images Zafemy
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 24 images provide visual information about the product associated with Zafemy NDC 42291-930 by Avkare, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
1 - 930 01
This is a description of Zafemy, a transdermal contraceptive system that contains norelgestromin and ethinyl estradiol in the amount of 150/35 mcg per day. The product is indicated only for transdermal use and is offered in a 1-week therapy pack. The given NDC (National Drug Code) number is 4220193001. No further information or details about the product are provided.*
3 - 930 03
Where to put patch - zafemy norelgestromin and ethinyl estradiol transd 1
Figure 4 - zafemy norelgestromin and ethinyl estradiol transd 10
Not available.*
Figure 5 - zafemy norelgestromin and ethinyl estradiol transd 11
Figure 6 - zafemy norelgestromin and ethinyl estradiol transd 12
01 - zafemy norelgestromin and ethinyl estradiol transd 13
02 - zafemy norelgestromin and ethinyl estradiol transd 14
This text appears to be a calendar, but the format is not clear due to errors. The days of the week are readable as "Sunday, Monday, Tuesday, Wednesday, Thursday, Friday, Saturday." However, the format of the calendar is not clear, and the text "Day8 wei" and "Day15s wed" do not provide any useful information. The text at the bottom of the page reads "NOPATCH."*
03 - zafemy norelgestromin and ethinyl estradiol transd 15
Figure A - zafemy norelgestromin and ethinyl estradiol transd 16
Figure B - zafemy norelgestromin and ethinyl estradiol transd 17
Where to put patch - zafemy norelgestromin and ethinyl estradiol transd 18
Usage Illustration 1 - zafemy norelgestromin and ethinyl estradiol transd 19
Usage Illustration 1 - zafemy norelgestromin and ethinyl estradiol transd 2
Usage Illustration 2 - zafemy norelgestromin and ethinyl estradiol transd 20
Usage Illustration 3 - zafemy norelgestromin and ethinyl estradiol transd 21
Usage Illustration 4 - zafemy norelgestromin and ethinyl estradiol transd 22
Usage Illustration 2 - zafemy norelgestromin and ethinyl estradiol transd 3
Usage Illustration 3 - zafemy norelgestromin and ethinyl estradiol transd 4
Usage Illustration 4 - zafemy norelgestromin and ethinyl estradiol transd 5
Figure 2 - zafemy norelgestromin and ethinyl estradiol transd 6
This text appears to be a table presenting data on the occurrence of blood clots in women according to their pregnancy status and time since delivery. It includes information on the number of women per 10,000 woman-years who experienced blood clots, categorized by pregnancy status (non-pregnant, pregnancy, and postpartum) and time since delivery. There are also some numerical ranges provided without further context.*
1 - zafemy norelgestromin and ethinyl estradiol transd 7
This appears to be a list of studies conducted on the risk of breast cancer with combined oral contraceptive use. The list includes the names of the studies, the year they were conducted, and the effect estimates obtained from each study. There are also some numerical values listed at the bottom, but without context, it's unclear what they represent.*
Structural Formula - zafemy norelgestromin and ethinyl estradiol transd 8
Figure 3 - zafemy norelgestromin and ethinyl estradiol transd 9
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.